Should I buy or sell Iterum Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITRM shares. View ITRM analyst ratings or view top-rated stocks .

What is Iterum Therapeutics' stock price target for 2024?

1 Wall Street research analysts have issued 12 month price objectives for Iterum Therapeutics' shares. Their ITRM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price. View analysts price targets for ITRM or view top-rated stocks among Wall Street analysts .

How have ITRM shares performed in 2024?

Iterum Therapeutics' stock was trading at $1.97 at the beginning of the year. Since then, ITRM stock has decreased by 23.9% and is now trading at $1.50. View the best growth stocks for 2024 here .

When is Iterum Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ITRM earnings forecast .

How were Iterum Therapeutics' earnings last quarter?

Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same quarter in the prior year, the company posted ($5.10) EPS.

When did Iterum Therapeutics' stock split?

Shares of Iterum Therapeutics reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Iterum Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE) , Viking Therapeutics (VKTX) , Acasti Pharma (ACST) , Axsome Therapeutics (AXSM) , Innovate Biopharmaceuticals (INNT) , OPKO Health (OPK) , VYNE Therapeutics (VYNE) , Fulcrum Therapeutics (FULC) , Ocugen (OCGN) .

When did Iterum Therapeutics IPO?

Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.

How do I buy shares of Iterum Therapeutics?

Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:ITRM

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Free ITRM Stock Alerts

$1.46

-0.11 (-7.01%)

(As of 11:15 AM ET)

Compare

Today's Range: $1.45
▼
$1.55
50-Day Range: $1.24
▼
$1.87
52-Week Range: $0.62
▼
$2.50

Volume: 112,361 shs
Average Volume: 541,868 shs
Market Capitalization: $23.99 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.00

Get Iterum Therapeutics alerts:

Iterum Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 300.0% Upside
$6.00 Price Target
Short Interest: Bearish
9.40% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.75) to ($1.27) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.82 out of 5 stars

Medical Sector

647th out of 930 stocks

Pharmaceutical Preparations Industry

297th out of 433 stocks

3.5

Analyst's Opinion

Consensus Rating
Iterum Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Iterum Therapeutics has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
9.40% of the float of Iterum Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Iterum Therapeutics has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Iterum Therapeutics has recently increased by 1.65%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Iterum Therapeutics does not currently pay a dividend.
Dividend Growth
Iterum Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ITRM.

3.8

News and Social Media Coverage

News Sentiment
Iterum Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Iterum Therapeutics this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for ITRM on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
2 people have added Iterum Therapeutics to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iterum Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 5.40% of the stock of Iterum Therapeutics is held by insiders.
Percentage Held by Institutions
Only 9.21% of the stock of Iterum Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Iterum Therapeutics are expected to grow in the coming year, from ($1.75) to ($1.27) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Iterum Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iterum Therapeutics is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Iterum Therapeutics Stock (NASDAQ:ITRM)

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

ITRM Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ITRM Stock News Headlines

April 2, 2024 | finance.yahoo.com

Iterum Therapeutics plc (NASDAQ:ITRM) Q4 2023 Earnings Call Transcript

March 30, 2024 | seekingalpha.com

Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 29, 2024 | finance.yahoo.com

Q4 2023 Iterum Therapeutics PLC Earnings Call

March 28, 2024 | finanznachrichten.de

Iterum Therapeutics PLC: Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 28, 2024 | globenewswire.com

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

March 21, 2024 | globenewswire.com

Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024

March 15, 2024 | globenewswire.com

Iterum Therapeutics to Participate in H.C. Wainwright Virtual @Home Fireside Chat

April 16, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

March 12, 2024 | markets.businessinsider.com

EQS-News: Mainz Biomed Presents ColoAlert® at UDH Congress 2024: Leading the Way in Evidence-Based Cancer Screening Innovations

March 6, 2024 | finance.yahoo.com

Iterum Therapeutics Provides Business Update

February 28, 2024 | investing.com

Iterum Therapeutics PLC (ITRM)

February 24, 2024 | msn.com

Iterum Therapeutics (ITRM) Price Target Increased by 550.00% to 6.63

February 1, 2024 | finance.yahoo.com

Steven Cohen's Point72 Asset Management Acquires New Stake in Iterum Therapeutics PLC

February 1, 2024 | msn.com

Iterum Shareholders Reject Board’s Share Issuance Proposal

January 31, 2024 | msn.com

Iterum Therapeutics Announces Triumph in Phase 3 uUTI Trial

January 30, 2024 | msn.com

Why Iterum Therapeutics Stock Is Trending Today

January 30, 2024 | msn.com

Iterum meets main goal in late trial for uUTI treatment with oral sulopenem

January 30, 2024 | markets.businessinsider.com

Iterum Therapeutics's Late-stage REASSURE Trial Successfully Met Primary Endpoint

January 30, 2024 | marketwatch.com

Iterum Therapeutics Says UTI Drug Trial Met Primary Endpoint

January 30, 2024 | marketwatch.com

Iterum Therapeutics Shares Surge on Positive UTI Drug Trial Results

January 30, 2024 | finance.yahoo.com

Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of Oral Sulopenem in Uncomplicated Urinary Tract Infections

December 28, 2023 | msn.com

Insiders Buying Iterum Therapeutics And 3 Other Stocks Under $3

November 29, 2023 | msn.com

Iterum Therapeutics director discloses purchase of 20K shares

November 15, 2023 | finance.yahoo.com

Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

November 15, 2023 | finance.yahoo.com

Q3 2023 Iterum Therapeutics PLC Earnings Call

November 14, 2023 | finanznachrichten.de

Iterum Therapeutics PLC: Iterum Therapeutics Reports Third Quarter 2023 Financial Results

See More Headlines

Receive ITRM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iterum Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/12/2021
Today: 4/16/2024
Next Earnings (Estimated): 5/10/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ITRM
CUSIP: N/A
CIK: 1659323
Web: www.iterumtx.com
Phone: (531) 669-4820
Fax: N/A
Employees: 14
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $6.00
High Stock Price Target: $6.00
Low Stock Price Target: $6.00
Potential Upside/Downside: +289.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.97)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-38,370,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -664.00%
Return on Assets: -87.64%

Debt

Debt-to-Equity Ratio: 3.63
Current Ratio: 1.89
Quick Ratio: 1.89

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.48) per share
Price / Book: -3.21

Miscellaneous

Outstanding Shares: 16,430,000
Free Float: 15,540,000
Market Cap: $25.30 million
Optionable: Not Optionable
Beta: 2.36

The Best High-Yield Dividend Stocks for 2024

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

Mr. Corey N. Fishman (Age 59)
President, CEO & Director
Comp: $1.37M
Ms. Judith M. Matthews (Age 54)
Chief Financial Officer
Comp: $778.82k
Dr. Michael W. Dunne M.D. (Age 64)
Strategic Advisor & Director
Comp: $168.15k
Dr. Sailaja Puttagunta M.D. (Age 55)
Chief Medical Officer
Comp: $755.89k
Mr. Tom Loughman Ph.D.
Senior Vice President of Technical Operations
Ms. Louise Barrett
Senior Vice President of Legal Affairs & Secretary
Dr. Steven I. Aronin M.D.
Senior VP & Head of Clinical Development

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ITRM Stock Analysis - Frequently Asked Questions

Should I buy or sell Iterum Therapeutics stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Iterum Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ITRM shares.
View ITRM analyst ratings or view top-rated stocks.
What is Iterum Therapeutics' stock price target for 2024?: 1 Wall Street research analysts have issued 12 month price objectives for Iterum Therapeutics' shares. Their ITRM share price targets range from $6.00 to $6.00. On average, they expect the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 300.0% from the stock's current price.
View analysts price targets for ITRM or view top-rated stocks among Wall Street analysts.
How have ITRM shares performed in 2024?: Iterum Therapeutics' stock was trading at $1.97 at the beginning of the year. Since then, ITRM stock has decreased by 23.9% and is now trading at $1.50.
View the best growth stocks for 2024 here.
When is Iterum Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024.
View our ITRM earnings forecast.
How were Iterum Therapeutics' earnings last quarter?: Iterum Therapeutics plc (NASDAQ:ITRM) posted its quarterly earnings data on Friday, November, 12th. The company reported $0.30 earnings per share for the quarter, missing the consensus estimate of $1.80 by $1.50. During the same quarter in the prior year, the company posted ($5.10) EPS.

When did Iterum Therapeutics' stock split?: Shares of Iterum Therapeutics reverse split on Thursday, August 18th 2022. The 1-15 reverse split was announced on Thursday, August 18th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, August 18th 2022. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.
What other stocks do shareholders of Iterum Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iterum Therapeutics investors own include Aeglea BioTherapeutics (AGLE), Viking Therapeutics (VKTX), Acasti Pharma (ACST), Axsome Therapeutics (AXSM), Innovate Biopharmaceuticals (INNT), OPKO Health (OPK), VYNE Therapeutics (VYNE), Fulcrum Therapeutics (FULC), Ocugen (OCGN).
When did Iterum Therapeutics IPO?: Iterum Therapeutics (ITRM) raised $80 million in an initial public offering (IPO) on Friday, May 25th 2018. The company issued 5,300,000 shares at $14.00-$16.00 per share. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Guggenheim Securities and Needham & Company were co-managers.
How do I buy shares of Iterum Therapeutics?: Shares of ITRM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ITRM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Iterum Therapeutics (ITRM) Stock Price, News & Analysis

Iterum Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Iterum Therapeutics Stock (NASDAQ:ITRM)

ITRM Stock Price History

ITRM Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders

ITRM Stock Analysis - Frequently Asked Questions

Overall MarketRank^™